Bruce Grossman Discloses 5.1% Stake in Applied DNA Sciences (ADNA)

TL;DR

**Investor Bruce Grossman just revealed a 5.1% stake in Applied DNA Sciences (ADNA).**

AI Summary

Bruce Grossman, an investor, reported beneficial ownership of 1,666,798 shares of Applied DNA Sciences, Inc. (ADNA) common stock as of February 2, 2024. This represents 5.1% of the company's outstanding shares. Grossman holds sole voting and dispositive power over 639,028 shares and shared voting and dispositive power over 1,027,770 shares. This matters to investors because a significant stake by an individual investor like Grossman could signal confidence in the company's future or, conversely, could lead to influence over corporate decisions.

Why It Matters

A substantial ownership stake by an individual investor like Bruce Grossman can influence company direction and stock performance, as large shareholders often have a say in strategic decisions.

Risk Assessment

Risk Level: low — This filing indicates a significant, but not controlling, stake by an individual investor, which generally presents low immediate risk to current shareholders.

Analyst Insight

Smart investors should monitor any future filings by Bruce Grossman (e.g., 13D if his intent changes to active engagement) and consider the potential implications of a significant individual shareholder on Applied DNA Sciences' governance and strategic decisions.

Key Numbers

• 1,666,798 — Total Shares Beneficially Owned (The aggregate number of shares of Applied DNA Sciences, Inc. common stock Bruce Grossman reported owning.)
• 5.1% — Percentage of Class (The percentage of Applied DNA Sciences, Inc.'s common stock that Bruce Grossman beneficially owns, indicating a significant stake.)
• 639,028 — Sole Voting/Dispositive Power Shares (The number of shares over which Bruce Grossman has complete control.)
• 1,027,770 — Shared Voting/Dispositive Power Shares (The number of shares over which Bruce Grossman shares control with others.)
• February 2, 2024 — Event Date (The specific date that triggered the requirement for this SC 13G filing.)

Key Players & Entities

• Bruce Grossman (person) — Reporting Person, investor in Applied DNA Sciences, Inc.
• Applied DNA Sciences, Inc. (company) — Subject Company, whose shares are being reported.
• Dillon Hill Capital LLC (company) — Address associated with Bruce Grossman's mailing address.
• 1,666,798 (dollar_amount) — Total shares beneficially owned by Bruce Grossman.
• 5.1% (dollar_amount) — Percentage of Applied DNA Sciences, Inc. common stock beneficially owned by Bruce Grossman.
• February 2, 2024 (person) — Date of event requiring the filing of this statement.

Forward-Looking Statements

• Bruce Grossman may seek to engage with Applied DNA Sciences management regarding strategic direction. (Bruce Grossman) — medium confidence, target: Within 6-12 months
• The stock price of Applied DNA Sciences could see increased volatility due to the disclosure of a significant new shareholder. (Applied DNA Sciences, Inc.) — low confidence, target: Within 1-3 months

FAQ

Filing Documents

• eh240447233_13g-adna.htm (SC 13G) — 41KB
• 0000950142-24-000358.txt ( ) — 42KB

From the Filing

SC 13G 1 eh240447233_13g-adna.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied DNA Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03815U201 (CUSIP Number) February 2, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 03815U201 SCHEDULE 13G Page 2 of 6 1 NAME OF REPORTING PERSON Bruce Grossman 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 639,028 6 SHARED VOTING POWER 1,027,770 7 SOLE DISPOSITIVE POWER 639,028 8 SHARED DISPOSITIVE POWER 1,027,770 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,666,798 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.8% 12 TYPE OF REPORTING PERSON IN CUSIP No. 03815U201 SCHEDULE 13G Page 3 of 6 Item 1. (a) Name of Issuer Applied DNA Sciences, Inc. (b) Address of Issuer’s Principal Executive Offices 50 Health Sciences Drive Stony Brook, New York 11790 Item 2. (a) Name of Person Filing Bruce Grossman (the “Reporting Person”) (b) Address of Principal Business Office or, if none, Residence c / o Dillon Hill Capital LLC 200 Business Park Drive, Suite 306 Armonk, NY 10504 (c) Citizenship USA (d) Title of Class of Securities Common Stock (e) CUSIP Number See cover page Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [__] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o) (b) [__] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c) (c) [__] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c) (d) [__] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8) (e) [__] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E) (f) [__] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) [__] A Parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G); (h) [__] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813) (i) [__] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3) (j) [__] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J). CUSIP No. 03815U201 SCHEDULE 13G Page 4 of 6 Item 4. The shares of Common Stock reported on this Schedule are indirectly beneficially owned by the Reporting Person. Dillon Hill Capital, LLC, of which the Reporting Person is the sole member, directly owns 639,028 shares of Common Stock of the Issuer. Dillon Hill Investment Company LLC, the investment decisions of which are controlled by the Reporting Person, directly owns 877,770 shares of Common Stock. Dillon Hill Investment Company II LLC, the investment decisions of which are controlled by the Reporting Person, directly owns 150,000 shares of Common Stock. The Reporting Person may be deemed to have sole voting and dispositive power over the shares of Common Stock held by Dillon Hill Capital LLC and shared voting and dispositive power over the shares of Common Stock held by Dillon Hill Investment Company LLC and Dillon Hill Investment Company II LLC. Dillon Hill Capital LLC also owns warrants to purchase 1,579,056 shares and Dillon Hill Investment Co LLC also owns warrants to purchase 2,157,739 shares of Common Stock. The exercise of these warrants are subject to limitations on beneficial ownership and approval of the Issuer’s shareholders. As a result, the shares of Common Stock issuable upon exercise of the warrants is not included in the ownership reported herein. The percentage beneficial ownership reported in It

View Full Filing

View this SC 13G filing on SEC EDGAR